TSCAN THERAPEUTICS Receives Bearish Rating After 13.76% Stock Drop: What’s in Store for the Future?
December 30, 2022
Trending News 🌧️
TSCAN THERAPEUTICS ($NASDAQ:TCRX) is a publicly traded biopharmaceutical company that specializes in the research and development of oncology-focused treatments. Recently, the company’s stock has dropped 13.76%, resulting in a Bearish rating from InvestorsObserver Sentiment Indicator. This drastic drop in stock price has left investors and analysts wondering what this means for the future of TSCAN THERAPEUTICS. The Bearish rating from InvestorsObserver Sentiment Indicator implies that the company’s stock will likely continue to decline in the near future. This could be due to a weak financial outlook, lack of investor confidence, or other potential reasons. The company’s current financials show that its revenue has been decreasing over the past year, which could be a sign that the company is struggling and may not be able to turn things around. Additionally, TSCAN THERAPEUTICS has yet to launch any products or treatments, which could also be influencing its stock price. Despite the recent decline, there is still potential for success for TSCAN THERAPEUTICS. The company has a strong team of researchers and scientists that are working hard to develop innovative treatments and products that could have a positive impact on the healthcare industry.
In addition, TSCAN THERAPEUTICS has secured partnerships with several major players in the industry, which could help to increase its visibility and ultimately lead to higher stock prices. Overall, the future of TSCAN THERAPEUTICS may be uncertain, but there is still potential for success. By continuing to develop innovative treatments and products, forming strategic partnerships, and improving its financial outlook, the company may be able to turn things around and regain investor confidence.
Share Price
At the time of writing, media coverage is mostly negative and investors are left wondering what the future holds for the company. On Tuesday, TSCAN THERAPEUTICS opened at $1.5 and closed at $1.5, down by 1.3% from prior closing price of 1.5. This is a significant decrease and has caused some concern about the potential for future losses. Despite the bearish rating, some investors remain hopeful that the company will be able to turn things around in the near future. It is unclear at this point how TSCAN THERAPEUTICS plans to recover from this setback, but it is likely that they will need to look at ways to reduce costs and increase efficiency in order to remain competitive in the market.
They may also need to look at ways to diversify their product offerings and explore new markets in order to increase their sales and profits. In the coming weeks, investors will be closely watching the movements of TSCAN THERAPEUTICS stock and monitoring their progress. It is possible that the company could still find success, but only time will tell if their efforts to turn things around will be successful. In the meantime, investors will have to wait and see how things develop before making any decisions about their investments. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Tscan Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 13.29 | -61.7 | -464.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Tscan Therapeutics. More…
| Operations | Investing | Financing |
| -64.87 | -5.06 | 29.37 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Tscan Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 165.45 | 48.8 | 4.85 |
Key Ratios Snapshot
Some of the financial key ratios for Tscan Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -462.7% |
| FCF Margin | ROE | ROA |
| -526.0% | -31.0% | -23.2% |
VI Analysis
Investing in company stocks can be a daunting task, especially when it comes to evaluating a company’s fundamentals. At VI, we take the hassle out of it by providing a simple and easy to understand analysis of a company’s financial and business aspects. TSCAN THERAPEUTICS, for example, has been given a low risk rating by VI, indicating its potential for long-term growth. This is based on our analysis of the company’s financial data, such as its balance sheet, income statement, and cash flow statement. We also take into consideration the company’s debt-to-equity ratio, operating performance and other key metrics. This risk rating is just the tip of the iceberg when it comes to understanding a company’s fundamentals. To get a comprehensive view of the company, register with us and access our detailed report on TSCAN THERAPEUTICS. Our reports provide you with insights into the company’s performance, operations, management style and other areas that may have potential risks. With this information in hand, you can make an informed decision on whether or not to invest in the company. More…
VI Peers
TScan Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of its proprietary T cell receptor scanning technology for the treatment of cancer and autoimmune diseases. The company’s primary competitors are Freeline Therapeutics Holdings PLC, PhaseBio Pharmaceuticals Inc, and Werewolf Therapeutics Inc.
– Freeline Therapeutics Holdings PLC ($NASDAQ:FRLN)
Freeline Therapeutics Holdings PLC is a biopharmaceutical company that focuses on the development and commercialization of gene therapies for chronic liver diseases. The company has a market cap of $42.89 million and a return on equity of -1.18%. Freeline’s lead product candidate, FLT180a, is in clinical development for the treatment of hemophilia B and other bleeding disorders. The company is also developing FLT190 for the treatment of Wilson disease.
– PhaseBio Pharmaceuticals Inc ($NASDAQ:PHAS)
Bio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer. The company’s lead product candidate is BIO-1402, a small molecule inhibitor of the PI3K/mTOR pathway. The company’s second product candidate is BIO-1210, a small molecule inhibitor of the HDAC family of enzymes.
– Werewolf Therapeutics Inc ($NASDAQ:HOWL)
Werewolf Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company’s lead product candidate, WTX-124, is a monoclonal antibody that targets the protein CD47, which is overexpressed on the surface of cancer cells and inhibits the body’s natural immune response to cancer. Werewolf Therapeutics is currently conducting a Phase 1/2 clinical trial of WTX-124 in patients with solid tumors.
The company’s market cap as of 2022 is 112.8M. The company has a Return on Equity of -28.8%.
Summary
TSCAN Therapeutics has seen its stock drop 13.76% recently and has received a bearish rating from investing analysts. Investors should consider multiple factors when evaluating the company’s potential, such as its financial performance, market conditions, competitive landscape, and management team. It is also important to consider potential risks, such as regulatory changes and potential competition. Ultimately, investing in TSCAN Therapeutics requires careful consideration of all available information and a thorough understanding of the company’s operations, prospects, and risks.
